Sitagliptin more effectively achieves a composite endpoint for A1C reduction,
lack of hypoglycemia and no body weight gain compared with glipizide.
Author(s): Seck TL, Engel SS, Williams-Herman DE, Sisk CM, Golm GT, Wang H, Kaufman KD,
Goldstein BJ.
Affiliation(s): Merck Sharp & Dohme Corp., Whitehouse Station, NJ, United States.
thomas_seck@merck.com
Publication date & source: 2011, Diabetes Res Clin Pract. , 93(1):e15-7
Sitagliptin and glipizide added to metformin provided similar degrees of glycemic
efficacy in patients with type 2 diabetes with inadequate glycemic control on
metformin monotherapy at 1 year; however, significantly more patients in the
sitagliptin group achieved an A1C reduction of >0.5% without hypoglycemia and
without an increase in body weight.
|
